Zentalis Pharmaceuticals, Inc. - common stock (ZNTL)
1.8850
-0.0450 (-2.33%)
Zentalis Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for the treatment of cancer
The company's expertise lies in its ability to identify and target specific molecular pathways that drive cancer growth and progression. Zentalis is dedicated to advancing a pipeline of small molecules designed to address high unmet medical needs in oncology. Through a combination of scientific rigor and a commitment to patient care, the company aims to deliver effective treatment options that can improve outcomes for individuals battling cancer.
The FDA has lifted the partial clinical hold on Zentalis Pharmaceuticals' azenosertib studies. Zentalis plans to work with trial investigators to continue development while presenting additional data later this year.
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of June 17-21, 2024.
